An intriguing LUAD DEP is B-cell lymphoma/leukemia10 (BCL10), which has a role in inflammation as part of the multiproteincomplex in the NF-κB pathway61,62 and thereforemay relate to the activation of EGFR.63 In B-cell lymphomas, trials for inhibitors targeting another proteinin the same complex, mucosa-associated lymphoid tissue protein 1 (MALT1),are ongoing, as well as efforts to understand their efficacy in solidcancers.64 This evidence concerns the gene EGFR and B-cell non-Hodgkin lymphoma.